Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations.

Kugel CH 3rd, Douglass SM, Webster MR, Kaur A, Liu Q, Yin X, Weiss SA, Darvishian F, Al-Rohil RN, Ndoye A, Behera R, Alicea GM, Ecker BL, Fane M, Allegrezza MJ, Svoronos N, Kumar V, Wang DY, Somasundaram R, Hu-Lieskovan S, Ozgun A, Herlyn M, Conejo-Garcia JR, Gabrilovich D, Stone EL, Nowicki TS, Sosman J, Rai R, Carlino MS, Long GV, Marais R, Ribas A, Eroglu Z, Davies MA, Schilling B, Schadendorf D, Xu W, Amaravadi RK, Menzies AM, McQuade JL, Johnson DB, Osman I, Weeraratna AT.

Clin Cancer Res. 2018 Nov 1;24(21):5347-5356. doi: 10.1158/1078-0432.CCR-18-1116. Epub 2018 Jun 13.

PMID:
29898988
2.

Frontline Science: Microbiota reconstitution restores intestinal integrity after cisplatin therapy.

Perales-Puchalt A, Perez-Sanz J, Payne KK, Svoronos N, Allegrezza MJ, Chaurio RA, Anadon C, Calmette J, Biswas S, Mine JA, Costich TL, Nickels L, Wickramasinghe J, Rutkowski MR, Conejo-Garcia JR.

J Leukoc Biol. 2018 May;103(5):799-805. doi: 10.1002/JLB.5HI1117-446RR. Epub 2018 Mar 14.

PMID:
29537705
3.

Estrogens drive myeloid-derived suppressor cell accumulation.

Conejo-Garcia JR, Payne KK, Svoronos N.

Oncoscience. 2017 Feb 24;4(1-2):5-6. doi: 10.18632/oncoscience.340. eCollection 2017 Jan. No abstract available.

4.

Trametinib Drives T-cell-Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis.

Allegrezza MJ, Rutkowski MR, Stephen TL, Svoronos N, Perales-Puchalt A, Nguyen JM, Payne KK, Singhal S, Eruslanov EB, Tchou J, Conejo-Garcia JR.

Cancer Res. 2016 Nov 1;76(21):6253-6265.

5.

Tumor Cell-Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells.

Svoronos N, Perales-Puchalt A, Allegrezza MJ, Rutkowski MR, Payne KK, Tesone AJ, Nguyen JM, Curiel TJ, Cadungog MG, Singhal S, Eruslanov EB, Zhang P, Tchou J, Zhang R, Conejo-Garcia JR.

Cancer Discov. 2017 Jan;7(1):72-85. doi: 10.1158/2159-8290.CD-16-0502. Epub 2016 Sep 30.

6.

BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.

Zhu H, Bengsch F, Svoronos N, Rutkowski MR, Bitler BG, Allegrezza MJ, Yokoyama Y, Kossenkov AV, Bradner JE, Conejo-Garcia JR, Zhang R.

Cell Rep. 2016 Sep 13;16(11):2829-2837. doi: 10.1016/j.celrep.2016.08.032.

7.

Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target.

Perales-Puchalt A, Svoronos N, Rutkowski MR, Allegrezza MJ, Tesone AJ, Payne KK, Wickramasinghe J, Nguyen JM, O'Brien SW, Gumireddy K, Huang Q, Cadungog MG, Connolly DC, Tchou J, Curiel TJ, Conejo-Garcia JR.

Clin Cancer Res. 2017 Jan 15;23(2):441-453. doi: 10.1158/1078-0432.CCR-16-0492. Epub 2016 Jul 19.

8.

Improved renal ischemia tolerance in females influences kidney transplantation outcomes.

Aufhauser DD Jr, Wang Z, Murken DR, Bhatti TR, Wang Y, Ge G, Redfield RR 3rd, Abt PL, Wang L, Svoronos N, Thomasson A, Reese PP, Hancock WW, Levine MH.

J Clin Invest. 2016 May 2;126(5):1968-77. doi: 10.1172/JCI84712. Epub 2016 Apr 18.

9.

IL15 Agonists Overcome the Immunosuppressive Effects of MEK Inhibitors.

Allegrezza MJ, Rutkowski MR, Stephen TL, Svoronos N, Tesone AJ, Perales-Puchalt A, Nguyen JM, Sarmin F, Sheen MR, Jeng EK, Tchou J, Wong HC, Fiering SN, Conejo-Garcia JR.

Cancer Res. 2016 May 1;76(9):2561-72. doi: 10.1158/0008-5472.CAN-15-2808. Epub 2016 Mar 15.

10.

Satb1 Overexpression Drives Tumor-Promoting Activities in Cancer-Associated Dendritic Cells.

Tesone AJ, Rutkowski MR, Brencicova E, Svoronos N, Perales-Puchalt A, Stephen TL, Allegrezza MJ, Payne KK, Nguyen JM, Wickramasinghe J, Tchou J, Borowsky ME, Rabinovich GA, Kossenkov AV, Conejo-Garcia JR.

Cell Rep. 2016 Feb 23;14(7):1774-1786. doi: 10.1016/j.celrep.2016.01.056. Epub 2016 Feb 11.

11.

The Tumor Macroenvironment: Cancer-Promoting Networks Beyond Tumor Beds.

Rutkowski MR, Svoronos N, Perales-Puchalt A, Conejo-Garcia JR.

Adv Cancer Res. 2015;128:235-62. doi: 10.1016/bs.acr.2015.04.011. Epub 2015 May 21. Review.

12.

Molecular adjuvant IL-33 enhances the potency of a DNA vaccine in a lethal challenge model.

Villarreal DO, Svoronos N, Wise MC, Shedlock DJ, Morrow MP, Conejo-Garcia JR, Weiner DB.

Vaccine. 2015 Aug 20;33(35):4313-20. doi: 10.1016/j.vaccine.2015.03.086. Epub 2015 Apr 14.

13.

Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation.

Rutkowski MR, Stephen TL, Svoronos N, Allegrezza MJ, Tesone AJ, Perales-Puchalt A, Brencicova E, Escovar-Fadul X, Nguyen JM, Cadungog MG, Zhang R, Salatino M, Tchou J, Rabinovich GA, Conejo-Garcia JR.

Cancer Cell. 2015 Jan 12;27(1):27-40. doi: 10.1016/j.ccell.2014.11.009. Epub 2014 Dec 18.

14.

Transforming growth factor β-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression.

Stephen TL, Rutkowski MR, Allegrezza MJ, Perales-Puchalt A, Tesone AJ, Svoronos N, Nguyen JM, Sarmin F, Borowsky ME, Tchou J, Conejo-Garcia JR.

Immunity. 2014 Sep 18;41(3):427-439. doi: 10.1016/j.immuni.2014.08.012.

15.

Initiation of metastatic breast carcinoma by targeting of the ductal epithelium with adenovirus-cre: a novel transgenic mouse model of breast cancer.

Rutkowski MR, Allegrezza MJ, Svoronos N, Tesone AJ, Stephen TL, Perales-Puchalt A, Nguyen J, Zhang PJ, Fiering SN, Tchou J, Conejo-Garcia JR.

J Vis Exp. 2014 Mar 26;(85). doi: 10.3791/51171.

16.

Pathological mobilization and activities of dendritic cells in tumor-bearing hosts: challenges and opportunities for immunotherapy of cancer.

Tesone AJ, Svoronos N, Allegrezza MJ, Conejo-Garcia JR.

Front Immunol. 2013 Dec 10;4:435. doi: 10.3389/fimmu.2013.00435. Review.

17.

A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.

Chiang CL, Kandalaft LE, Tanyi J, Hagemann AR, Motz GT, Svoronos N, Montone K, Mantia-Smaldone GM, Smith L, Nisenbaum HL, Levine BL, Kalos M, Czerniecki BJ, Torigian DA, Powell DJ Jr, Mick R, Coukos G.

Clin Cancer Res. 2013 Sep 1;19(17):4801-15. doi: 10.1158/1078-0432.CCR-13-1185. Epub 2013 Jul 9.

18.

The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy.

Finn JD, Nichols TC, Svoronos N, Merricks EP, Bellenger DA, Zhou S, Simioni P, High KA, Arruda VR.

Blood. 2012 Nov 29;120(23):4521-3. doi: 10.1182/blood-2012-06-440123. Epub 2012 Aug 23.

Supplemental Content

Loading ...
Support Center